ERBB2 and ocular melanoma: When compared a similar population of HR+/HER2‐ patients who were eligible for local therapy for OM, but instead only received chemotherapy without local control, the median PFS for paclitaxel21, 22 or docetaxel,23 antimicrotubular antineoplastics/capecitabine,21, 24 docetaxel/sunitinib,23 doxorubicin,22 doxorubicin/paclitaxel22 ranged between 6 and 10 months, though the majority of the patients in our cohort did not receive these specific agents concurrently with SABR.